A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.
Biliary Tract Cancer
DRUG: Nab-paclitaxel + Cisplatin|DRUG: Gemcitabine + Cisplatin
PFS, PFS is defined as time from the start of treatment to progression of disease or death., up to 3 years
ORR, The rate of participants that achieve either a complete response (CR) or a partial response (PR)., up to 3 years|OS, Overall survival is defined as time from the start of treatment until death due to any reason., up to 3 years|TTP, Time to progress is defined as time from randomized grouping to objective progression of tumors., up to 3 years|AEs, Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment., up to 3 years
It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.